CHADS2 Score Calculator
Calculate thromboembolic stroke risk in non-valvular atrial fibrillation (AFib) and assess anticoagulant indications using clinical consensus criteria.
Clinical Criteria
Clinical Precision & Methodology
The CHADS₂ score is a widely used clinical prediction rule for estimating the risk of stroke in patients with non-rheumatic atrial fibrillation (AF). It directs the administration of anticoagulant therapy.
Standardized Risk Stratification
The index accurately stratifies AF patients into low, moderate, and high risk categories based on prospective cohort data, providing a percentage stroke rate per 100 patient-years.
Guideline Concordance
Aligns with ACC/AHA/ESC guidelines for stroke prevention, highlighting critical antithrombotic intervention thresholds (Score ≥ 2 generally necessitates oral anticoagulation).
Thermal Receipt Export
Generates a high-resolution, perfectly scaled PNG image designed specifically for 80mm thermal printers, enabling instant clinical handouts.
Acronym Breakdown
CHADS₂ Score Tiers & Annual Ischemic Stroke Rates
Quantifying unanticoagulated thromboembolic risk in non-valvular atrial fibrillation to guide antithrombotic therapy in accordance with AHA/ACC clinical consensus guidelines and the CHADS2 risk model.
CHADS₂ Score 0
No Antithrombotic Therapy or Aspirin
Oral anticoagulation is not recommended. Low intrinsic thromboembolic risk does not outweigh bleeding hazards of systemic anticoagulation.
CHADS₂ Score 1
Oral Anticoagulation (DOAC) Preferred
Consider clinical factors, bleeding risk (HAS-BLED), and CHA₂DS₂-VASc re-stratification. DOACs or aspirin (81–325 mg) according to patient profile.
CHADS₂ Score 2
Systemic Anticoagulation Indicated
Strong consensus recommendation (ACC/AHA/ESC) for oral anticoagulation with direct oral anticoagulants (apixaban, rivaroxaban) or adjusted-dose warfarin.
CHADS₂ Score 3 – 6
Immediate Long-Term Anticoagulation
Severe thromboembolic vulnerability. Score 3 (5.9%), 4 (8.5%), 5 (12.5%), and 6 (18.2%). DOAC therapy strongly indicated unless strict contraindications exist.
The CHADS₂ Clinical Criteria & Scoring Points
Understanding the five independent cardiovascular variables contributing to Virchow's triad of atrial thrombus formation.
Congestive Heart Failure
Recent decompensated heart failure or documented moderate-to-severe left ventricular systolic dysfunction (LVEF ≤ 40%). Promotes stasis in the left atrial appendage.
Hypertension
Consistently documented resting BP > 140/90 mmHg or currently receiving active antihypertensive pharmacotherapy. Causes progressive atrial remodeling and endothelial shear stress.
Age ≥ 75 Years
Advanced chronological age exponentially accelerates vascular stiffness, atrial fibrosis, and coagulatory changes, independent of underlying systemic comorbidities.
Diabetes Mellitus
Fasting blood glucose ≥ 126 mg/dL, HbA1c ≥ 6.5%, or requiring oral hypoglycemic agents/insulin. Induces endothelial dysfunction and a chronic prothrombotic state.
Prior Stroke or TIA
History of documented ischemic cerebrovascular event, transient ischemic attack (TIA), or systemic thromboembolism. Represents the single strongest clinical predictor of recurrence.
Interconnected Clinical Calculators
Seamlessly combine AFib stroke risk evaluation with renal clearance calculations, blood gas mechanics, and hemodynamic monitoring.
GFR Calculator
Determine renal clearance with race-free CKD-EPI 2021 to calibrate DOAC drug dosages.
Child Dose Calculator
Calculate pediatric drug dosages from adult reference values using BSA and weight rules.
A-a Gradient Calculator
Evaluate alveolar-arterial oxygen differences to pinpoint causes of arterial hypoxemia.
Mean Arterial Pressure (MAP)
Assess systemic cardiovascular tissue perfusion pressure during hemodynamic resuscitation.
Frequently Asked Clinical Questions
Evidence-based medical answers on stroke risk stratification, antithrombotic recommendations, and privacy.
Q1.What clinical risk factors comprise the CHADS2 acronym?
The CHADS2 score assigns point values to five major independent stroke risk factors in non-valvular atrial fibrillation: Congestive Heart Failure (+1), Hypertension (+1), Age ≥ 75 years (+1), Diabetes Mellitus (+1), and Prior Stroke or Transient Ischemic Attack (TIA, +2).
Q2.How does the CHADS2 score stratify annual thromboembolic stroke risk?
Annual unanticoagulated ischemic stroke risk increases incrementally with score: 0 points (1.9%/year, low risk), 1 point (2.8%/year, intermediate risk), 2 points (4.0%/year, high risk), 3 points (5.9%), 4 points (8.5%), 5 points (12.5%), and 6 points (18.2%, very high risk).
Q3.When is anticoagulation therapy (DOACs vs Warfarin) clinically indicated?
Clinical consensus guidelines (ACC/AHA/ESC) strongly recommend systemic oral anticoagulation with direct oral anticoagulants (DOACs: apixaban, rivaroxaban, dabigatran, edoxaban) or adjusted-dose warfarin (target INR 2.0–3.0) for patients with a CHADS2 score ≥ 2, and individualized evaluation for a score of 1.
Q4.What is the clinical difference between the CHADS2 score and the CHA2DS2-VASc score?
CHA2DS2-VASc expands the original model by adding vascular disease history (+1), female sex (+1), and stratifying age into 65–74 (+1) and ≥75 (+2). CHA2DS2-VASc provides superior sensitivity for identifying truly 'low-risk' individuals (score of 0 in males or 1 in females) who can safely avoid anticoagulation.
Q5.Why are Congestive Heart Failure, Hypertension, and Diabetes independent stroke predictors in AFib?
Atrial fibrillation causes hemodynamic stasis in the left atrial appendage (LAA). Heart failure exacerbates atrial dilation, hypertension induces vascular endothelial shear injury, and diabetes triggers a hypercoagulable state with platelet hyperreactivity, fulfilling Virchow's triad for thrombus formation.
Q6.Is my cardiac medical history or stroke risk profile stored on Utilvo?
No. All risk calculations, stroke rate estimations, and thermal report renders are performed 100% client-side in your local browser sandbox. No patient identifiers, cardiovascular diagnoses, or clinical findings are ever logged or transmitted across the network.
Cardiology Guidelines & Stroke Prevention Sources
AHA/ACC GuidelineThromboembolic risk score stratifications (CHADS2 and CHA2DS2-VASc) and oral anticoagulant (DOAC/Warfarin) recommendations adhere to published AHA, ACC, and ESC clinical cardiology practice guidelines.
The tools and information provided on this site are for educational purposes only and do not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition.
This page is researched and reviewed by Utilvo's content team against publicly available clinical guidelines and reputable health sources. It is not a substitute for advice from a licensed healthcare provider.